CLINICAL OBSERVATION FROM THE TREATMENT OF ICOTINIB FOR 196 CASES WITH ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Gu, Qin A. [1 ]
Han, Hui B. [1 ]
Jiang, Yan L. [1 ]
Wang, Min H. [1 ]
Shi, Lei C. [1 ]
Xiong, Wen L. [1 ]
Zhao, Zhuo Y. [1 ]
Chu, Qing T. [1 ]
Pei, Jun [1 ]
机构：
[1] Jiaotong Uniyers, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
ADVANCED NSCLC; EGFR-TKI; Icotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-012
引用
收藏
页码：S598 / S598
页数：1
相关论文
共 50 条
  • [41] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
    Huang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S431 - S432
  • [42] KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
    Marta Román
    Iosune Baraibar
    Inés López
    Ernest Nadal
    Christian Rolfo
    Silvestre Vicent
    Ignacio Gil-Bazo
    Molecular Cancer, 17
  • [43] Clinical Observation of EGFR-TKI Combined With 89Sr in the Treatment of Non-Small Cell Lung Cancer With Osteoblastic Reaction
    Jia, Y.
    Li, T.
    Jiang, Y.
    Zhong, L. Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S599 - S599
  • [44] Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
    Bersanelli, Melissa
    Tiseo, Marcello
    Artioli, Fabrizio
    Lucchi, Leonardo
    Ardizzoni, Andrea
    ANTICANCER RESEARCH, 2014, 34 (06) : 3185 - 3188
  • [45] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [46] The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer
    Ernani, Vinicius
    Steuer, Conor E.
    Jahanzeb, Mohammad
    ANNUAL REVIEW OF MEDICINE, VOL 68, 2017, 68 : 153 - 168
  • [47] Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
    Mandrekar, Sumithra J.
    Qi, Yingwei
    Hillman, Shauna L.
    Ziegler, Katie L. Allen
    Reuter, Nicholas F.
    Rowland, Kendrith M., Jr.
    Kuross, Steven A.
    Marks, Randolph S.
    Schild, Steven. E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 3 - 9
  • [48] FUNCTIONAL DECLINE IN PATIENTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER
    Murnane, Andrew
    Krishnasamy, Meinir
    Denehy, Linda
    Granger, Catherine
    Mileshkin, Linda
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1240 - S1240
  • [49] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Pistamaltzian, Nikolaos F.
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
  • [50] Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer
    Ganti, Apar
    Hirsch, Fred R.
    Wynes, Murry
    Ravelo, Arliene
    Ramalingam, Suresh
    Ionescu-Ittu, Raluca
    Pivneva, Irina
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S964 - S965
12345